C
Clene Inc. (CLNN)
NCM – Real vaqt narxi. Valyuta: USD
6.50
0.00 (0.00%)
Yopilishda: May 12, 2026, 4:00 PM EDT
6.23
-0.27 (-4.15%)
Bozor oldidan: May 13, 2026, 6:23 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.50
0.00 (0.00%)
Yopilishda: May 12, 2026, 4:00 PM EDT
6.23
-0.27 (-4.15%)
Bozor oldidan: May 13, 2026, 6:23 AM EDT
Clene Inc., klinik bosqichdagi farmatsevtika kompaniyasi, yangi toza sirtli nanotech (CSN) terapevtik vositalarni kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniyaning asosiy dori nomzodi CNM-Au8 bo'lib, u turli klinik sinovlarda o'rganilmoqda, shu jumladan amiotrofik lateral skleroz (ALS) bilan og'rigan bemorlarda CNM-Au8 ning xavfsizligi va samaradorligini baholash uchun yakunlangan 2-bosqich platforma sinovi; simptomatik ALS bilan og'rigan bemorlarda 2-bosqich kontseptsiya klinik sinovi yakunlangan; miya energiya metabolitlari bo'yicha ikki ochiq tadqiqotchi ko'r-ko'rona 2-bosqich klinik sinovlari yakunlangan; surunkali optik nevropatiyada ko'z nur yo'llarining nuqsonlarini davolash, barqaror relapsli ko'p sklerozda remiyelinatsiyani ta'minlash uchun 2-bosqich klinik sinovi yakunlangan; va Parkinson kasalligi bilan og'rigan bemorlarni davolash uchun ikkinchi 2-bosqich klinik sinovi. Kompaniya yuqumli kasalliklarni davolash va yaralarning bitishini qo'llab-quvvatlash uchun ishlab chiqilayotgan kumush va rux ionlarining jel polimer suspenziyasi bo'lgan CNM-AgZn17; va yuqumli kasallikni davolash va simptomlarni hal qilish uchun immunitetni qo'llab-quvvatlash uchun keng spektrli antiviral va antibakterial vosita bo'lgan CNM-ZnAg ishlab chiqadi. Bundan tashqari, kompaniya rMetx, rux-kumush ionlarining suvli parhez qo'shimchasini o'z ichiga olgan parhez qo'shimchalarini sotadi va tarqatadi; va KHC46, juda past konsentratsiyali Au nanozarralarining suvli oltin parhez qo'shimchasi. Clene Inc.ning shtab-kvartirasi Yuta shtatining Salt-Leyk-Siti shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Benjamin M. Greenberg M.D., M.H.S. | Head of Medical |
| Mr. Jerry Miraglia J.D. | General Counsel & Corporate Secretary |
| Mr. Mark G. Mortenson ESQ. | Chief Science Officer |
| Mr. Michael T. Hotchkin | Chief Development Officer |
| Mr. Morgan R. Brown CPA, M.B.A. | Chief Financial Officer |
| Mr. Robert Etherington MBA | CEO, President & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 8-K | clnn20260417_8k.htm |
| 2026-05-04 | 8-K | clnn20260503_8k.htm |
| 2026-04-10 | DEFA14A | clnn20260324_defa14a.htm |
| 2026-04-10 | DEF 14A | clnn20250512_def14a.htm |
| 2026-03-17 | 8-K | clnn20260316_8k.htm |
| 2026-03-17 | 10-K | clnn20251231_10k.htm |
| 2026-03-12 | 8-K | clnn20251022_8k.htm |
| 2026-02-24 | 8-K | clnn20260223_8k.htm |
| 2026-01-13 | 8-K | clnn20260106_8k.htm |
| 2026-01-12 | 8-K | clnn20260109_8k.htm |
| Ms. Mary Anne Mcneil | Head of Human Resources |